Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 10/20 | 0.68 |
| ▸ | KDR | P35968 | 7/20 | 0.68 |
| ▸ | EGFR | P00533 | 6/20 | 0.68 |
| ▸ | FLT1 | P17948 | 1/20 | 0.68 |
| ▸ | KIF5B | P33176 | 5/20 | 0.62 |
| ▸ | LCK | P06239 | 1/20 | 0.62 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12227578 | 0.91 | RET (0.70) | RETKDREGFRFLT1KIF5B | |
| SCHEMBL7154199 | 0.88 | RET (0.72) | RETKDREGFRFLT1KIF5B | |
| SCHEMBL13271524 | 0.85 | KDR (0.61) | RETKDREGFRFLT1KIF5B | |
| SCHEMBL12200787 | 0.82 | RET (0.74) | RETKDREGFRFLT1KIF5B | |
| SCHEMBL7116324 | 0.81 | SRC (0.75) | RETKDREGFRFLT1KIF5B | |
| SCHEMBL7116313 | 0.81 | RET (0.73) | RETKDREGFRFLT1KIF5B | |
| SCHEMBL5864529 | 0.81 | KDR (1.00) | RETKDREGFRFLT1KIF5B | |
| SCHEMBL5865250 | 0.81 | EGFR (1.00) | RETKDREGFRFLT1KIF5B | |
| SCHEMBL7076160 | 0.81 | RET (1.00) | RETKDREGFRFLT1KIF5B | |
| SCHEMBL5864606 | 0.81 | EGFR (1.00) | RETKDREGFRFLT1KIF5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090047278-A1 | Novel Combinational Use of Sulfonamide Compound | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1859793-A1 | NOVEL COMBINATIONAL USE OF SULFONAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047278-A1 | Novel Combinational Use of Sulfonamide Compound | EGFR, KIT, ERBB2 | RET 15/4885KDR 31/4885EGFR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.